Manila Times Business
Xeltis exceeds 50% enrollment in US Pivotal trial for aXess™, its vascular access device for hemodialysis
US pivotal trial is a multi-center study evaluating a bioabsorbable hemodialysis vascular access implant across complex hemodialysis patients representing real-world practice> 50% of target enrollment reached across 20 sites in the United States EINDHOVEN, The Netherlands, July 02, 2026 (GLOBE NEWSWIRE) -- Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today announces that it has reached 50% enrollment in its US pivotal
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
TIMEX GROUP TAKES FULL OWNERSHIP OF DANIEL WELLINGTON
1h ago
Innoscience Secures Removal of Court-Enjoined Infineon GaN Products from Display at electronica China 2026
1h ago
Elis continues to expand its network in Brazil with the acquisition of ServBrazil
1h ago
Aedifica NV/SA: Publication relating to a transparency notification
1h ago